Nostrum Laboratories Inc. (Nostrum), located in Missouri and New Jersey, and its founder and CEO, Nirmal Mulye, Ph.D. (Mulye), have agreed to pay a minimum of $3,825,000, and up to $50 million if certain financial contingencies are met, to resolve allegations that they violated the False Claims Act by knowingly underpaying Medicaid rebates due for Nostrum’s drug Nitrofurantoin Oral Suspension (Nitro OS). The settlement is based on Nostrum’s and Mulye’s financial condition. Read More
Home » Drugmaker Nostrum and Its CEO Agree to Pay Up to $50 Million to Settle False Claims Act Claims for Underpaying Rebates Owed Under Medicaid Drug Rebate Program
Drugmaker Nostrum and Its CEO Agree to Pay Up to $50 Million to Settle False Claims Act Claims for Underpaying Rebates Owed Under Medicaid Drug Rebate Program
Related Posts
Former Principals of Aerospace Start-Up Charged with Fraud and Tax Crimes
An indictment was unsealed charging five former principals of Theia Group Inc., a Washington, D.C.-based aerospace start-up company, with conspiracy and fraud. Read More
Wealthy Miami Man Pleads Guilty to Decades-Long Scheme to Defraud the
A Miami man pleaded guilty to conspiring with others to defraud the United States by concealing millions of dollars in assets and income in undisclosed… BronWealthy Miami Man Pleads Guilty to Decades-Long Scheme to Defraud the
Leaders of Los Zetas, a Violent Mexican Drug Cartel, Arraigned on Drug
Mexican nationals and former leaders of the Los Zetas cartel were arraigned today in Washington, D.C., on charges of engaging in a continuing criminal enterprise… BronLeaders of Los Zetas, a Violent Mexican Drug Cartel, Arraigned on Drug